PATENT CLAIM ANALYSIS

Application Number: 15889893
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "254040"]

Abstract:
A preparation for oral administration comprising: a pregelatinized starch comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboxyimide hydrochloride (lurasidone) represented by the formula (1) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, the preparation exhibiting an invariant level of elution behavior even when the content of its active ingredient is varied.

Claim (Index 9):
The tablet of  claim 6 , comprising more than 40 mg up to 120 mg of lurasidone, wherein the second tablet comprises 20 mg to 40 mg of lurasidone.

Metadata:
- Claim Count in Document: 79.0
- Percentile: 88.0
- Lexical Diversity: 1.46429
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14733204', '11919678', '14512189', '14183283', '10381036']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8294515794766145
- 35 USC 102 Novelty (BERT): 0.6152484015727308
- Combined Prediction Score: 0.8080312616862262
- Mean Citation Score: 535.981714
- Max Citation Score: 597.18396
- Similarity Product: 504.0470288375902

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test